⚠️
Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Elevated cost per beneficiary
Risk indicators are statistical patterns, not allegations. Learn more
3,671
Total Claims
$2.6M
Drug Cost
413
Beneficiaries
$6,378
Cost/Patient
Risk Score Breakdown 3/100
Low (0)Moderate (15)Elevated (30)High (50+)
Cost per patient outlier+3
Score components are additive. Read full methodology
Peer Comparison vs. 6,382 Endocrinology providers
+62%
Cost per patient vs peers
$6,378 vs $3,933 avg
+13%
Brand preference vs peers
57.7% vs 51.2% avg
Brand vs Generic
42% generic
Brand: 1,983 claims · $2.5M
Generic: 1,452 claims · $53K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Semaglutide | 242 | $406K |
| Tirzepatide | 258 | $351K |
| Dulaglutide | 148 | $301K |
| Teriparatide | 45 | $254K |
| Empagliflozin | 190 | $250K |
| Insulin Aspart | 73 | $61K |
| Insulin Degludec | 68 | $58K |
| Insulin Lispro | 70 | $57K |
| Sitagliptin Phosphate | 25 | $48K |
| Insulin Degludec | 69 | $46K |
| Insulin Aspart | 23 | $45K |
| Insulin Lispro | 15 | $40K |
| Linagliptin | 26 | $39K |
| Liraglutide | 13 | $38K |
| Semaglutide | 17 | $37K |
Prescribing Profile
Patient Profile
74
Avg Age
68%
Female
1.42
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations.Methodology · About